Pre-made Pagibaximab benchmark antibody (Whole mAb, anti-Staphylococcus epidermidis lipoteichoic acid therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-944

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-944 Category Tag

Product Details

Anti-Staphylococcus epidermidis lipoteichoic acid therapeutic antibody (Pre-made Pagibaximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March?21[update], it is undergoing Phase II/III clinical trials.[1][2]

Products Name (INN Index)

Pre-Made Pagibaximab Biosimilar, Whole Mab: Anti-Staphylococcus Epidermidis Lipoteichoic Acid therapeutic antibody

INN Name

pagibaximab

Target

Staphylococcus epidermidis lipoteichoic acid

Format

Whole mAb

Derivation

Chimeric

Species Reactivity

Human

CH1 Isotype

IgG1 – kappa

VD LC

IgG1 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

MedImmune (Gaithersburg MD USA) / AstraZeneca (London UK)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

Staphylococcus epidermidis lipoteichoic acid

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide